[HIV infection among type A and B hemophiliacs]

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

[HIV infection among type A and B hemophiliacs]

Rev Fr Transfus Hemobiol. 1993 Oct;36(5):417-26. Unique Identifier : AIDSLINE MED/94082786
Vicariot M; Fressinaud E; Fiks M; Fonlupt J; Berthier AM; Guerois C; Fimbel B; Centre de Traitement de l'hemophilie, CHR de Brest.

Abstract: Evolution of HIV infection was studied in 480 hemophiliacs A and 78 hemophiliacs B treated in the Centre-West Region. 23.3% hemophiliacs A and 46.1% hemophiliacs B were contaminated by HIV. In this region, HIV seroprevalence in hemophiliacs A was lower than the prevalence noted at the national level (51.2%); this is certainly due to the use of frozen cryoprecipitates in the treatment of a high number of hemophiliacs A. A higher number of hemophiliacs B developed the disease: 12.5% hemophiliacs A versus 22% hemophiliacs B. Moreover hemophilic B patients had a more rapid evolution towards the disease since 6 out of 14 hemophiliacs A and 7 out of 8 hemophiliacs B with AIDS died. The fact that hemophiliacs B were significantly older than hemophiliacs A might be one of the reasons, but it must be noted that the contamination often occurred earlier in hemophiliacs B and was perhaps more important. The more severe evolution in the hemophiliac B group noted in our region is not found in American studies, which may be due to the different ways of preparing Factor IX concentrates in France and the United States.

Keywords: Adolescence Adult Aged Blood Donors Blood Transfusion/*ADVERSE EFFECTS Child Child, Preschool Christmas Disease/*EPIDEMIOLOGY/THERAPY Comorbidity Comparative Study Drug Contamination English Abstract Factor IX/*THERAPEUTIC USE Factor VIII/*THERAPEUTIC USE France/EPIDEMIOLOGY Hemophilia/*EPIDEMIOLOGY/THERAPY Human HIV Infections/*EPIDEMIOLOGY/ETIOLOGY/MORTALITY/TRANSMISSION *HIV Seroprevalence Infant Life Tables Middle Age Retrospective Studies Risk Factors Survival Analysis JOURNAL ARTICLE MULTICENTER STUDY
940330
M9430451

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .